Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag for Poor Graft Function After Allogeneic Hematopoietic Cell Transplantation
2018-001157-27Phase 2Terminated
- Sponsor
- CHU de Lille
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eltrombopag in poor graft function (PGF), sponsored by CHU de Lille. Primary endpoint: Platelet response at 12 weeks. Started Oct 2018; status: terminated.
02
Drugs
eltrombopag
03
Conditions
poor graft function (PGF)
Beyond the preview
Go deeper on 2018-001157-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001157-27.